A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-21 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
The thyroid gland also produces the hormone calcitonin, which helps regulate blood calcium levels. Parafollicular cells produce calcitonin in response to high blood calcium. Calcitonin decreases the release of calcium from bone, by decreasing the activity of osteoclasts, cells which break down bone. Bone is constantly reabsorbed by osteoclasts and created by osteoblasts, so calcitonin effectively stimulates movement of calcium into bone. The effects of calcitonin are opposite those of the parathyroid hormone (PTH) produced in the parathyroid glands. However, calcitonin seems far less essential than PTH, since calcium metabolism remains clinically normal after removal of the thyroid (thyroidectomy), but not the parathyroid glands.
Cyclopia intermedia, known as 'bergtee' (mountain tea), found between Port Elizabeth and the edge of the Langkloof Cyclopia genistoides, known as 'kustee' (coastal tea), found mostly in the Western Cape near Yzerfontein and Darling and also thriving in the South Cape if cultivated Cyclopia maculata, grown in the Outeniqua area near George Cyclopia sessiliflora, known as 'Heidelberg-tee', named after the town Heidelberg in South Africa, where it grows in the local mountain range Cyclopia subternata, known as 'vleitee' (marshland tea) or 'valleitee' (valley tea) Cyclopia longifolia Some species can be cultivated whereas others have resisted all attempts at cultivation and must be harvested in the wild. It is not always easy to discover what the seeds need to enable them to germinate; some kinds bear elaiosomes and might be dependent on the services of particular ants or birds. Cyclopia intermedia (mountain tea) is one of the teas that is harvested in the Kouga mountains where it grows naturally. Mountain tea regenerates within three years after harvesting or devastation by fire; consequently less than one third of the mountain yield is available for harvesting each year by rotation. Mountain tea and valley tea flower in September/October whereas coastal tea flowers in May/June.
=== Transmission === B. canis is commonly transmitted during sexual intercourse, as well as physical contact with infected bodily fluids. B. canis is passed through contact with fluids from the mucous membranes of the genitals (semen and vaginal discharge), eyes, and oronasal cavities. The highest bacterial loads of B. canis are found in the genital secretions of dogs infected with the bacteria. Contact can occur during sexual activity as well as other daily grooming and social interactions. Though dog-to-dog transmission is most commonly during breeding, it can also happen after contact with uterine discharge, semen, and aborted material. High levels of B. canis exist in these secretions in the six weeks following abortion in females, and around six to eight weeks following infection in males. Lower levels of B. canis still remain in the semen of infected males for two years following infection, which can serve as a large source of transmission to other dogs. Offspring of infected females can be infected with B. canis through intrauterine vertical transmission or via drinking the milk of the infected female. Urine can also serve as a route of transmission in males, as the bladder resides in close proximity to the prostate and epididymus. The bacterial load in the urine of infected dogs is lower than in genital discharges. In their urine, infected dogs can carry up to 106 bacteria per milliliter, compared to the genital discharges that can carry up to 1010 bacteria per milliliter. This leads to contamination of the urine making it another vehicle for B. canis transmission.
Sources: en.wikipedia.org
=== Metabolic niche partitioning === In 2010, exometabolomics analysis of the cyanobacterium, Synechococcus sp. PCC 7002 by Baran, et al. revealed that this photoautotroph could deplete a diverse pool of exogenous metabolites. A follow-up exometabolomics study on sympatric microbial isolates from biological soil crust, which exist in communities with cyanobacteria in the desert soils of the Colorado Plateau, suggested that metabolite niche partitioning exists in these communities, where each isolate only utilizes 13-26% of metabolites from the soil
Orlando Figes (born 1959) historian, author, known for works on Russian history; has also contributed on European history with his book The Europeans (2019); has served on editorial board of journal Russian History; writes for international press, broadcasts on television and radio, reviews for The New York Review of Books, and is fellow of Royal Society of Literature; was historical consultant on film Anna Karenina starring Keira Knightley and Jude Law with screenplay by Tom Stoppard; historical consultant on BBC War & Peace television series. Antonia Forest (26 May 1915 – 28 November 2003) was the pseudonym of Patricia Giulia Caulfield Kate Rubinstein, an English writer. She wrote 13 books for children, published between 1948 and 1982. Her 10 best-known works concern the doings of the fictional Marlow family. Forest also wrote two historical novels about the Marlows' Elizabethan ancestors. Dov Forman (b. 2003); author and social media creator; uses social media to educate people about the Holocaust and Judaism, and to advocate against antisemitism; co-authored Lily's Promise, a book documenting the Holocaust; received the 'Points of Light' award for services to Holocaust education; included in the inaugural TIME100 Creators list; was selected for the inaugural Masa Changemakers List, honouring 18 global leaders from Masa's 200,000+ alumni. Forman was a Masa participant during his time in Israel as a Nitzavim Fellow, studying at the Hebrew University of Jerusalem and a Talmudic college in Jerusalem.
==== Blood-cell formation ==== The specificity of the human immune-cell repertoire is what allows the human body to defend itself from rapidly adapting antigens. However, the immune system is vulnerable to degradation upon the pathogenesis of disease, and because of the critical role that it plays in overall defense, its degradation is often fatal to the organism as a whole. Diseases of hematopoietic cells are diagnosed and classified via a subspecialty of pathology known as hematopathology. The specificity of the immune cells is what allows recognition of foreign antigens, causing further challenges in the treatment of immune disease. Identical matches between donor and recipient are no longer required for successful transplantation. Rather, haploidentical matches have facilitated numerous transplants, given improvements in post-transplant immunosuppressive regimens. Research using both hematopoietic adult stem cells and embryonic stem cells has provided insight into the possible mechanisms and methods of treatment for many of these ailments. Fully mature human red blood cells may be generated ex vivo by hematopoietic stem cells (HSCs), which are precursors of red blood cells. In this process, HSCs are grown together with stromal cells, creating an environment that mimics the conditions of bone marrow, the natural site of red-blood-cell growth. Erythropoietin, a growth factor, is added, coaxing the stem cells to complete terminal differentiation into red blood cells.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.